LY 3499446
Alternative Names: LY3499446Latest Information Update: 04 Jul 2025
At a glance
- Originator Eli Lilly and Company
- Class Antineoplastics
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 25 Apr 2025 Pharmacodynamics data from a pre-clinical trial in Non-small cell lung cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 11 Oct 2023 Pharmacodynamics data from preclinical studies in Non small cell lung cancer presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)
- 14 Apr 2023 Pharmacodynamics data from a preclinical trial in Non small cell lung cancer presented at 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)